Isoxsuprine

DB08941ApprovedWithdrawnSmall moleculeAdrenergic AgonistsAdrenergic beta-Agonists

Isoxsuprine is a beta-adrenergic agonist used in the symptomatic treatment of cerebrovascular insufficiency, peripheral vascular disease of arteriosclerosis obliterans, thromboangiitis obliterans (Buerger's disease) and Raynaud's disease. A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle.

Chemical structure of Isoxsuprine
Mechanism
Curator reviewed
Formula / weight
C18H23NO3 · 301.386 g/mol (avg)
First approval
United States, 1996

Resolves to

Compound
UNIIR15UI3245NCAS395-28-8PubChem11779629
Clinical / RWD
RxNorm6066ATCC04AA01
Structure
InChIKeyBMUKKTUHUDJSNZ-HBUWYVDXSA-NSMILESC[C@H](COC1=CC=CC=C1)N[C@H](C)[C@@H](O)C1=CC=C(O)C=C1
Targets
P07550ADRB2

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
821Drug interactionsStructured to mechanism, not free text
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
6Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
2ContraindicationsEach with its own population and attribute set
Sign in
24Marketed productsAcross 3 countries and 16 labellers
Sign in
1ATC codeIncluding every combination product, plus 23 drug categories
Sign in
18+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Isoxsuprine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In